Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial
Enregistré dans:
Auteurs principaux: | Andreas Kjær, Peter Rossing, Emilie H Zobel, Asger Wretlind, Rasmus S Ripa, Viktor Rotbain Curovic, Bernt J von Scholten, Tommi Suvitaival, Tine W Hansen, Cristina Legido-Quigley |
---|---|
Format: | article |
Langue: | EN |
Publié: |
BMJ Publishing Group
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/cccfc22306d64967a2e1646bd7183cb0 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [64Cu]Cu-DOTATATE PET/CT: Results from the LIRAFLAME Trial
par: Jacob K. Jensen, et autres
Publié: (2021) -
Effect of liraglutide on expression of inflammatory genes in type 2 diabetes
par: Emilie H. Zobel, et autres
Publié: (2021) -
The effect of liraglutide and sitagliptin on oxidative stress in persons with type 2 diabetes
par: Suvanjaa Sivalingam, et autres
Publié: (2021) -
Author Correction: Intravital imaging of islet Ca2+ dynamics reveals enhanced β cell connectivity after bariatric surgery in mice
par: Elina Akalestou, et autres
Publié: (2021) -
Ceramide Remodeling and Risk of Cardiovascular Events and Mortality
par: Linda R. Peterson, et autres
Publié: (2018)